May 14, 2020
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
Apr 30, 2020
Achieve Life Sciences Announces Private Placement of $1.9 Million
Mar 13, 2020
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
Mar 12, 2020
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
Dec 19, 2019
Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Dec 17, 2019
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
Dec 09, 2019
Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
Nov 06, 2019
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
Sep 30, 2019
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
Sep 13, 2019
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 05, 2019
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
Sep 04, 2019
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
Aug 08, 2019
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update
Jul 23, 2019
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
Jun 21, 2019
Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
Jun 03, 2019
Achieve Receives $4.2 Million from Exercise of Warrants
May 07, 2019
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
Apr 24, 2019
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
Apr 03, 2019
Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019